Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03551795
Other study ID # iNKT20180427V1.1
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date January 1, 2018
Est. completion date March 31, 2022

Study information

Verified date May 2022
Source Shanghai Public Health Clinical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Invariant Natural killer T (iNKT) cells are a unique subset of lymphocytes that express homogeneous TCR recognizing KRN7000 which was up-regulated by many kinds of cancer cells.The hypothesis of the investigators is that immunotherapy strategy of infusion of iNKT cells may resist inflection and decrease the tumor burden and improve overall survival. The purpose of this study is to assess the safety and efficacy of treatment of tuberculosis with malignant solid tumor by infusing of iNKT cells.


Description:

Treatment of tuberculosis with malignant solid tumor is great unsolved challenge to the physicians. Efficacy of conventional treatment, such as surgery, radiotherapy and chemotherapy is limited. AS novel therapy, immunotherapy shows great prospects. Human iNKT cells can directly lysis tumor cells by a perforin-dependent mechanism,and intracellular granzyme B expression may also potentiate cell killing. Tumor cells expressing CD1d may be especially susceptible to direct NKT cell lysis. iNKT cells play important role in immune regulation by secreting various cytokines. Expansion method of iNKT cells in vitro is developed as published in the patent of the investigators. Infusion of iNKT cells has been proved safe in mice. In this clinical trial, the safety and efficacy of the immunotherapy of infusion of iNKT cells are assessed.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date March 31, 2022
Est. primary completion date December 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Histological or cytologically diagnosis of tuberculosis with malignant solid tumor - Patients' tumor tissue (formalin-fixed, paraffin-embedded) must be sufficient for diagnosis of cancer by a certified Laboratory of Pathology - Laboratory values within the following ranges prior to receiving treatment of study agent: Hemoglobin?8.0 g/dL, Neutrophils count?1E9/L, Lymphocytes count?lower limit of institutional normal, Platelet count?50E9/L, Serum creatinine?2.0 mg/dL, Serum bilirubin?2 x upper limit of institutional normal, AST/ALT?2 x upper limit of institutional normal - No dyspnea at rest. Oxygen saturation =90% on room air - No genetic disease - Fertile females/males must consent to use contraceptives during participation of the trial. Women of child bearing potential must have a negative pregnancy test prior to receiving treatment of study agent within 7 days - Patients must have a Karnofsky performance status greater than or equal to 80% - Able and willing to give witnessed, written informed consent form prior to receiving any study related procedure - Agrees to participate in long-term follow-up for up to 1 years, if received NKT infusion Exclusion Criteria: - Organ dysfunction,such as significant cardiovascular disease, myocardial infarction within the past six months, unstable angina, coronary angioplasty within the past six months, uncontrolled atrial or ventricular cardiac arrhythmias; Child-Pugh C; Renal function failure or uremia; Respiratory failure; Disturbance of consciousness; Renal failure. - Suffering from lymphoma or leukemia - Serious infections requiring antibiotics, bleeding disorders - Patients with myelodysplastic syndrome (MDS) - History of immunodeficiency disease or autoimmune disease - Positive HIV antigen and antibody, Hepatitis B surface antigen and Hepatitis C PCR within 21 days prior to enrollment - Within concurrent chemotherapy - Concurrent other medical condition that would prevent the patient from undergoing protocol-based therapy - Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dose of study agent - Pregnant or breast-feeding patients - Can't give informed consent - Lack of availability for follow-up assessment

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Infusion of iNKT cells
The eligible patients receive twice infusions of iNKT cells(1E8~1E10) in one course of treatment.

Locations

Country Name City State
China Shanghai Public Health Clinical Center, Fudan University Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Xiaoyan Zhang

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Progression-Free Survival (PFS) Progression-Free Survival (PFS) Approximately 1 years after the treatment
Primary Objective Response Rate (ORR) Change of target focus confirmed by CT or MRI up to 4 months post-infection
Secondary Incidence of adverse events related to the infusion of cells The incidence of adverse events following infusion of iNKT cells 28 days post-infusion
See also
  Status Clinical Trial Phase
Terminated NCT01846429 - Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain Phase 1
Completed NCT01359982 - Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects Phase 1
Completed NCT00725634 - A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma Phase 1
Completed NCT01648764 - A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread Phase 1
Recruiting NCT04083599 - GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT05141474 - Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors Early Phase 1
Active, not recruiting NCT02999750 - EXtendedAnalysis for Cancer Treatment N/A
Completed NCT01457118 - An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies Phase 2
Active, not recruiting NCT05539157 - Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors Phase 1
Recruiting NCT04571892 - A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT05468359 - Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients Phase 1/Phase 2
Recruiting NCT04168528 - Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT Phase 1/Phase 2
Recruiting NCT04145622 - Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors Phase 1/Phase 2
Recruiting NCT06057038 - A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors Phase 1
Completed NCT02844400 - Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation
Completed NCT00452413 - A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer Phase 1/Phase 2
Completed NCT03553108 - A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours. Phase 1
Recruiting NCT06391775 - Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy Phase 1/Phase 2
Recruiting NCT04076137 - Targeted T-cell Therapy in Solid Tumors Early Phase 1
Terminated NCT03192345 - A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors Phase 1